MedTrace Logo

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

NCT05794880 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-05-13

No results posted yet for this study

Summary

This is a single arm pilot study for patients with hematologic malignancies receiving unrelated or haploidentical related mobilized peripheral stem cells (PSCs) using the CliniMACS system for alpha/beta T cell depletion plus CD19+ B cell depletion with individualized ALC-based dosing of ATG to study impact on engraftment, GVHD, and disease free survival

Conditions

  • Leukemia
  • Acute Myeloid Leukemia in Remission
  • Myelodysplasia
  • Acute Lymphoblastic Leukemia in Remission
  • Chronic Myelogenous Leukemia - Chronic Phase
  • Chronic Myelogenous Leukemia, Accelerated Phase
  • Chronic Myelogenous Leukemia With Crisis of Blast Cells
  • Biphenotypic Acute Leukemia
  • Lymphoblastic Lymphoma
  • Burkitt Lymphoma
  • Burkitt Leukemia
  • Lymphoma After Relapse
  • Other Malignant Hematologic Diseases in Remission

Interventions

DEVICE

Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)

Participants in this study will receive a blood stem cell transplant, which will use an investigational device called the CliniMACs device to remove alpha/beta T cells and B cells from the blood cells collected from the donor. This is called T cell depletion and B cell depletion.

Sponsors & Collaborators

  • Medical College of Wisconsin

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
0 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-01
Primary Completion
2027-05-31
Completion
2032-05-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05794880 on ClinicalTrials.gov